BIOLASE (OTCPK:BIOL) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

BIOL 주식 개요

는 자회사와 함께 미국 및 전 세계에서 치과 의사와 환자를 위한 레이저 시스템을 개발, 제조, 마케팅 및 판매합니다.

BIOL 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	0/6
과거 실적	0/6
재무 상태	2/6
배당금	0/6

보상

위험 분석

cash runway 경력이 1년 미만입니다.

의미 있는 시가총액이 없습니다. ( $4M )

지난 1년 동안 주주가 크게 희석되었습니다.

최근 3개월간 주가 변동폭 심해

+ 1 더 많은 위험

BIOLASE, Inc. 경쟁사

Predictive Oncology

NasdaqCM:POAI

US$4.6m

INVO Bioscience

NasdaqCM:INVO

US$3.4m

LumiraDx

OTCPK:LMDX.F

US$6.1m

Nuwellis

NasdaqCM:NUWE

US$3.9m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 BIOLASE
과거 주가
현재 주가	US$0.072
52주 최고치	US$10.31
52주 최저치	US$0.036
베타	0.75
11개월 변경	-62.71%
3개월 변경 사항	-60.07%
1년 변경 사항	-99.08%
33년 변화	-100.00%
5년 변화	-100.00%
IPO 이후 변화	-100.00%

최근 뉴스 및 업데이트

Recent updates

BIOLASE - Good News Across The Board But Still Only Suited For The Most Speculative Investors

Nov 24

Is BIOLASE (NASDAQ:BIOL) Using Debt Sensibly?

Jul 14

Biolase shares jump 11% after regaining Nasdaq compliance

Feb 04

Biolase: Business Recovery On The Way But Warrant Overhang Should Keep Investors Sidelined

Feb 01

주주 수익률

	BIOL	US Medical Equipment	US 마켓
7D	-50.1%	0.4%	0.4%
1Y	-99.1%	-0.6%	22.9%

수익률 대 산업: BIOL 지난 1년 동안 -0.5 %를 반환한 US Medical Equipment 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: BIOL 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is BIOL's price volatile compared to industry and market?
BIOL volatility
BIOL Average Weekly Movement	21.2%
Medical Equipment Industry Average Movement	7.7%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	2.9%

안정적인 주가: BIOL 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: BIOL 의 주간 변동성( 17% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
1984	157	John Beaver	www.biolase.com

는 자회사와 함께 미국 및 전 세계에서 치과 의사와 환자를 위한 레이저 시스템을 개발, 제조, 마케팅 및 판매하고 있습니다. 치과 레이저 시스템을 통해 치과의사, 치주과 전문의, 신경치료 전문의, 소아치과 전문의, 구강외과 전문의 및 기타 치과 전문의는 미용, 수복 및 복잡한 수술 분야를 포함한 다양한 최소침습 치과 시술을 수행할 수 있습니다. 이 회사는 연조직 및 경조직 절단을 위한 워터라제 전조직 치과 레이저 시스템, 연조직, 위생, 일시적 통증 완화, 치아 미백 및 미용 시술을 위한 다이오드 연조직 레이저 시스템, 비수술적 치주염 관리 및 임상 생산성 향상을 위한 에픽 위생 레이저를 제공합니다.

BIOLASE, Inc. 기본 사항 요약

BIOLASE 의 수익과 매출은 시가총액과 어떻게 비교하나요?
BIOL 기본 통계
시가총액	US$4.31m
수익(TTM)	-US$38.25m
수익(TTM)	US$48.83m

0.0x

P/S 비율

-0.1x

P/E 비율

BIOL 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
BIOL 손익 계산서(TTM)
수익	US$48.83m
수익 비용	US$32.11m
총 이익	US$16.72m
기타 비용	US$54.98m
수익	-US$38.25m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-1.15
총 마진	34.25%
순이익 마진	-78.35%
부채/자본 비율	5,207.1%

BIOL 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

BIOL 주식 개요

보상

위험 분석

BIOLASE, Inc. 경쟁사

NasdaqCM:POAI

US$4.6m

NasdaqCM:INVO

US$3.4m

OTCPK:LMDX.F

US$6.1m

NasdaqCM:NUWE

US$3.9m

가격 내역 및 성능

최근 뉴스 및 업데이트

BIOLASE, Inc.(OTCPK:BIOL) dropped from NASDAQ Composite Index

Nasdaq Hearings Panel Determines to Delist BIOLASE's Common Stock

Biolase Receives an Additional Staff Determination Letter from Nasdaq Regarding Non-Compliance with Minimum $2.5 Million Stockholders’ Equity Requirement for Continued Listing Set in Nasdaq Listing Rule 5550(b)

BIOLASE, Inc. Reiterates Earnings Guidance for the Full-Year of 2024

BIOLASE, Inc. to Report Q1, 2024 Results on May 13, 2024

BIOLASE Receives Staff Determination Letter from Nasdaq Regarding Failure to Meet the Minimum Closing Bid Price Requirement as Required by Listing Rule 5550(a)(2)

Recent updates

BIOLASE, Inc.(OTCPK:BIOL) dropped from NASDAQ Composite Index

Nasdaq Hearings Panel Determines to Delist BIOLASE's Common Stock

Biolase Receives an Additional Staff Determination Letter from Nasdaq Regarding Non-Compliance with Minimum $2.5 Million Stockholders’ Equity Requirement for Continued Listing Set in Nasdaq Listing Rule 5550(b)

BIOLASE, Inc. Reiterates Earnings Guidance for the Full-Year of 2024

BIOLASE, Inc. to Report Q1, 2024 Results on May 13, 2024

BIOLASE Receives Staff Determination Letter from Nasdaq Regarding Failure to Meet the Minimum Closing Bid Price Requirement as Required by Listing Rule 5550(a)(2)

BIOLASE, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

BIOLASE, Inc. to Report Q4, 2023 Results on Mar 21, 2024

BIOLASE, Inc., Annual General Meeting, May 02, 2024

BIOLASE Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price

BIOLASE, Inc. has completed a Composite Units Offering in the amount of $7.031795 million.

Nasdaq Grants Extension to BIOLASE, Inc. to Regain Compliance with the Stockholders' Equity Continued Listing Requirement

BIOLASE, Inc. Provides Earnings Guidance for the Full-Year 2023

BIOLASE, Inc. Provides Earnings Guidance for the Year 2024

Dr. Carol Gomez Summerhays Intends to Resign as Member of the Board of Directors of Biolase, Inc

BIOLASE, Inc. Successfully Concludes Waterlase iPlus All Tissue Laser Trial

BIOLASE, Inc. has filed a Follow-on Equity Offering.

BIOLASE Receives Non-Compliance Notice From Nasdaq

BIOLASE, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023

BIOLASE, Inc. Announces Study Performed by the Independent Mcguire Institute Confirms Positive 12 Month Clinical Outcomes for Biolase Repair(R) Perio Protocol

BIOLASE, Inc. to Report Q3, 2023 Results on Nov 09, 2023

BIOLASE, Inc. has completed a Composite Units Offering in the amount of $4.5 million.

BIOLASE Provides Non-Compliance Update

BIOLASE, Inc. Provides Earnings Guidance for the Second Half of 2023

BIOLASE, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Listing Qualifications Staff of Nasdaq Determines to Delist BIOLASE's Common Stock from the Nasdaq Capital Market and to Suspend Trading of the Common Stock at the Opening of Business on June 20 2023

BIOLASE, Inc. has completed a Composite Units Offering.

BIOLASE, Inc. has completed a Composite Units Offering.

BIOLASE, Inc. to Report Q1, 2023 Results on May 11, 2023

BIOLASE, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

BIOLASE Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

BIOLASE, Inc. has completed a Follow-on Equity Offering in the amount of $9.635963 million.

BIOLASE, Inc. has completed a Follow-on Equity Offering in the amount of $9.635963 million.

PIPStek LLC Files Patent Infringement Lawsuit Against BIOLASE

BIOLASE, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2022

BIOLASE, Inc. to Report Q3, 2022 Results on Nov 10, 2022

BIOLASE, Inc. Appoints Russell Morrow as Chief Dental Officer, Effective November 1, 2022

Biolase partners with dental speciality programs across U.S.

BIOLASE, Inc. Provides Revenue Forecast for the Third Quarter Ending September 30, 2022 and Full Year of 2022

BIOLASE, Inc. Provides Revenue Forecast for the Third Quarter Ending September 30, 2022 and Full Year of 2022

BIOLASE, Inc. to Report Q2, 2022 Results on Aug 11, 2022

BIOLASE: Ongoing Operating Losses, Capital Raises To Sustain Liquidity

BIOLASE, Inc. Appoints Steven Sandor to Chief Operating Officer

BIOLASE amends senior secured term loan with SWK Funding

BIOLASE, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

BIOLASE, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2022

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

High number of new directors

BIOLASE, Inc. Announces Election of Board of Directors

BIOLASE, Inc. to Report Q1, 2022 Results on May 12, 2022

BIOLASE: Bad News Across The Board - Sell

Price target decreased to US$2.13

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Is BIOLASE (NASDAQ:BIOL) Weighed On By Its Debt Load?

BIOLASE, Inc. Provides Revenue Guidance for the Fourth Quarter of 2021

BIOLASE - Speculative Buy After Strong Preliminary Q4 Results

BIOLASE and EdgeEndo Announce FDA 510(k) Clearance of New EdgePRO Laser-Assisted Microfluidic Irrigation Device for Endodontists

BIOLASE - Good News Across The Board But Still Only Suited For The Most Speculative Investors

Nasdaq Grants BIOLASE 180-Day Extension to Meet Minimum Bid Price Requirement